हिंदी में पढ़ें

Dr Reddy's Laboratories

Dr Reddy's Labs gets Rs 27 lakh penalty from Mexican drug regulator

Dr Reddy's Labs gets Rs 27 lakh penalty from Mexican drug regulator

Thu, Nov 14, 2024

The fine was imposed due to an error in the date of the invoice and also in the name of the reference standard versus import license.

Dr Reddy's fined Rs 28 lakh by Mexican drug regulator

Dr Reddy's fined Rs 28 lakh by Mexican drug regulator

Thu, Sep 26, 2024

The drug regulatory body of Mexico has imposed a penalty of MXN 6,51,420 (Rs 28 Lakh) on the company for deviation from prescribed guidelines for filing intimation of import of a reference standard for one of the active pharmaceutical ingredient

Dr Reddy's Laboratories share price: Company gets establishment inspection report from USFDA for Visakhapatnam units

Dr Reddy's Laboratories share price: Company gets establishment inspection report from USFDA for Visakhapatnam units

Mon, Aug 12, 2024

Earlier, the USFDA had issued a Form 483 with two observations to the two units following inspection which was conducted from May 8 to May 17, 2024.

TRENDING NOW

TOP GAINER on Nifty, Dr Reddy’s Laboratories rises 5% today; expert pegs target price at Rs 5400-Rs 5450, stop-loss Rs 4950

TOP GAINER on Nifty, Dr Reddy’s Laboratories rises 5% today; expert pegs target price at Rs 5400-Rs 5450, stop-loss Rs 4950

Tue, Apr 20, 2021

Dr Reddy’s Laboratories share price: Technical Analyst, Simi Bhaumik says that the Pharma sector will remain in focus and will see buying till the market remains weak on increasing Covid fears. The stock can see a target of Rs 5400 – Rs 5450 from here on and stop-loss can be Rs 4950. She suggested fresh buying should be done on dips. Dr. Reddy's Laboratories share price today is Rs 5188, up Rs 220 or 4.5%

Dr Lal Pathlabs outperformed its peers even as markets plummeted; Analyst Simi Bhaumik recommends a Buy for this target price

Dr Lal Pathlabs outperformed its peers even as markets plummeted; Analyst Simi Bhaumik recommends a Buy for this target price

Mon, Apr 12, 2021

While the stock markets plummeted on Monday, the Nifty Pharma index did better than most of its peers. Though it ended in the red, the fall was just under 0.3 per cent from the previous closing price.

Dr Reddy's Laboratories reports Q3 net profit of Rs 27.9 cr

Dr Reddy's Laboratories reports Q3 net profit of Rs 27.9 cr

Fri, Jan 29, 2021

Dr Reddy's Laboratories on Friday posted a consolidated net profit of Rs 27.9 crore for the third quarter ended December 31, 2020. The company had posted a net loss of Rs 538.4 crore during the same period of the previous fiscal.

Sputnik V clinical trial is about to begin: Saumen Chakraborty, CFO, Dr Reddy’s Laboratories

Sputnik V clinical trial is about to begin: Saumen Chakraborty, CFO, Dr Reddy’s Laboratories

Fri, Oct 30, 2020

Dr Reddy’s has launched 20 products so far in this financial year, says Saumen Chakraborty, Chief Financial Officer, Dr Reddy's Laboratories. During a chat with Swati Khandelwal, Zee Business, Chakraborty said, the trial of sputnik about to start and we have around 100 patients in Phase-II and 1,500 in phase-III.

Trials of Russian Sputnik-V vaccine may end as early as March: Dr Reddy''s

Wed, Oct 28, 2020

Drugmaker Dr Reddy`s Laboratories Ltd on Wednesday rolled out a preliminary timeline for the India trials of Russia`s coronavirus vaccine candidate, with the late-stage expected to be completed by as early as March 2021.

Dr Reddy's seeks DCGI nod for conducting phase-3 clinical trial of Russian COVID-19 vaccine Sputnik V

Dr Reddy's seeks DCGI nod for conducting phase-3 clinical trial of Russian COVID-19 vaccine Sputnik V

Sat, Oct 03, 2020

The Hyderabad-based Dr Reddy's Laboratories has applied to the Drugs Controller General of India for permission to conduct phase-3 human clinical trials of the Russian vaccine Sputnik V against COVID-19 in India, sources said.

Dr Reddy's Share price skyrockets near 13 pct; stock market experts suggest this strategy to mint money

Dr Reddy's Share price skyrockets near 13 pct; stock market experts suggest this strategy to mint money

Fri, Sep 18, 2020

Dr Reddy's share price has skyrocketed around 13 per cent in the intraday trade session. Dr Reddy's share price today shot up over Rs 625 to hit Rs 5,423 per share mark today.

Stocks in Focus on September 18: Dr Reddy's, Cipla, Lupin, Happiest Minds Technologies to HDFC Bank; here are expected newsmakers of the day

Stocks in Focus on September 18: Dr Reddy's, Cipla, Lupin, Happiest Minds Technologies to HDFC Bank; here are expected newsmakers of the day

Fri, Sep 18, 2020

Stocks in Focus on September 18: Dr Reddy's, Cipla, Lupin, Happiest Minds Technologies, HDFC Bank, etc. are expected newsmakers throughout the intraday trade session.

Dr Reddy's Laboratories Q1 net profit soars 45% to Rs 663 crore

Dr Reddy's Laboratories Q1 net profit soars 45% to Rs 663 crore

Mon, Jul 29, 2019

Pharma major Dr Reddy's Laboratories (DRL) on Monday reported a handsome 45.31 per cent growth in net profit for the first quarter ended June.

Dr Reddys to spend upto $300 million on R&D in FY 20

Dr Reddys to spend upto $300 million on R&D in FY 20

Mon, May 20, 2019

The R&D spend for the quarter (January-March FY 19) is Rs 366 crore, that is USD 53 million and EBIT 9.19 per cent of the sales for the quarter, said Saumen Chakraborty, President, CFO and global head (HR) of Dr Reddy.

Dr Reddy's, KKR appoint ex Axis Bank chief Shikha Sharma as independent director

Dr Reddy's, KKR appoint ex Axis Bank chief Shikha Sharma as independent director

Fri, Feb 01, 2019

Sharma will advising them on areas for business growth, value-creation opportunities and strategic mergers and acquisitions, an official statement said.

Pharma sector outlook 2019 in India: Expect big recovery in New Year; IPCA, Divis Lab champions of 2018

Pharma sector outlook 2019 in India: Expect big recovery in New Year; IPCA, Divis Lab champions of 2018

Mon, Dec 31, 2018

The sector has been volatile throughout the year due to constant news flow in the markets. Some giants of the sector witnessed objections over their manufacturing plants and medicine pricing in the U.S. markets.

Big blow to Dr Reddy's over opioid addiction treatment block in US; share price tanks a whopping 11%

Big blow to Dr Reddy's over opioid addiction treatment block in US; share price tanks a whopping 11%

Mon, Jul 16, 2018

Analysts at Jefferies believe injunction is a negative surprise for Dr Reddy’s and risks for FY20-22 EPS estimates have increased after the ruling. retain “underperform”, cuts TP to 1,850 rupees from 1,910 rupees

FAST MONEY: Phoenix Mills, Biocon among 20 intraday money-making ideas

FAST MONEY: Phoenix Mills, Biocon among 20 intraday money-making ideas

Mon, Jun 25, 2018

S&P500 mini futures fell as much as 0.5 per cent in early trade while MSCI's broadest index of Asia-Pacific shares outside Japan fell 0.2 per cent. Japan's Nikkeilost 0.4 percent.

Dr Reddy's last day on Sensex; stock rallies 20% in 8 sessions

Dr Reddy's last day on Sensex; stock rallies 20% in 8 sessions

Fri, Jun 15, 2018

Dr Reddy's share price gained as much as 20 per cent in the last 8 sessions, thanks to a renewed optimism on the sector. Nifty Pharma index itself gained 14 per cent during the same period. In Friday's trade, Nifty Pharma was the top sectoral gainer, led by gains in Dr Reddy's.

Sensex, Nifty reverse gains; Rupee at 10-week low as US Fed signals rate hike

Sensex, Nifty reverse gains; Rupee at 10-week low as US Fed signals rate hike

Thu, Sep 21, 2017

In pre-market opening, the 31-scrip index was trading lower at 32,406-level and that of 51-scrip index was below 10,140-mark.

Dr Reddy's Q4 net profit rises by 319%

Dr Reddy's Q4 net profit rises by 319%

Fri, May 12, 2017

GV Prasad, Co-Chairman and CEO of Dr Reddy's Laboratories said, “FY17 has been challenging year due to lack of new product approvals for the US market. However, our other geoghraphies delivered good performance with several new product launches.”

Dr Reddy's Laboratories Q4 review: Here's what to expect

Dr Reddy's Laboratories Q4 review: Here's what to expect

Fri, May 12, 2017

In Q3FY17, the company reported consolidated net profit of Rs 492.3 crore, down 15.94% year-on-year compared to Rs 585.7 crore in the corresponding period of the previous year.

Next set of Q4 corporate earnings, macro data, French elections result to drive equities this week

Next set of Q4 corporate earnings, macro data, French elections result to drive equities this week

Sun, May 07, 2017

According to experts, the stock markets this week will be guided by the fourth quarter (Q4) corporate earnings, macroeconomic data and French elections results.

Q3FY17: Dr Reddy's Laboratories' net profit down 19% at Rs 470 crore

Q3FY17: Dr Reddy's Laboratories' net profit down 19% at Rs 470 crore

Sat, Feb 04, 2017

GV Prasad, Co-chairman of Dr Reddy's Laboratories said, "Our performance in Q3 has delivered a modest sequential revenue growth of 3% over the previous quarter. Our EBITDA has improved significantly from the last quarter to Rs 8.8 billion, on the back of enhanced emphasis on operational efficiencies and controlling of SG&A cost across all our business."

Load More

LIVE TV

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x